5-Fluorouracil
Pyrimidine antimetabolite in USP/EP/BP/IP grade for IV injectable and topical formulation manufacturing. Sourced for colorectal, breast, and head & neck cancer treatment protocols.
Pharmaceutical & Life Science Solutions
Cytotoxic agents, targeted kinase inhibitors, antimetabolites, and hormone-pathway APIs for oncology and oncology-adjacent indications. Supplied in pharmaceutical grade for IV, oral, and topical formulation manufacturing.
Pyrimidine antimetabolite in USP/EP/BP/IP grade for IV injectable and topical formulation manufacturing. Sourced for colorectal, breast, and head & neck cancer treatment protocols.
Oral fluoropyrimidine prodrug in USP/EP grade for tablet formulation manufacturing, converted to 5-FU in tumour tissue. Sourced for metastatic breast and colorectal cancer product lines.
Semi-synthetic taxane in pharmaceutical grade (anhydrous and trihydrate forms available) for IV infusion formulation manufacturing. Sourced for breast, lung, prostate, and ovarian cancer treatment protocols.
Dual 5-alpha reductase inhibitor in pharmaceutical grade for soft gelatin capsule manufacturing. Primarily sourced for benign prostatic hyperplasia formulation lines, with research use in prostate cancer chemoprevention.
Topoisomerase II inhibitor in pharmaceutical grade (≥95% HPLC purity) for capsule and IV solution formulation manufacturing. Sourced for testicular cancer, small-cell lung cancer, and lymphoma treatment protocols.
Type II 5-alpha reductase inhibitor in pharmaceutical grade for tablet formulation manufacturing. Primarily sourced for benign prostatic hyperplasia and androgenetic alopecia product lines.
Nucleoside analogue antimetabolite supplied as hydrochloride salt — EP grade — for lyophilised IV infusion formulation manufacturing. Sourced for pancreatic, lung, bladder, and breast cancer treatment protocols.
BCR-ABL tyrosine kinase inhibitor mesylate salt supplied in beta (thermodynamically stable) and alpha crystalline polymorphic forms for tablet formulation manufacturing. Sourced for CML, ALL, and GIST treatment protocols.
Taxane mitotic inhibitor in USP/EP grade for IV infusion and albumin-bound nanoparticle formulation manufacturing. Sourced for breast, ovarian, lung cancer, and Kaposi's sarcoma treatment protocols.
Antifolate agent supplied as disodium salt — the standard parenteral trading form — for lyophilised IV infusion formulation manufacturing. Sourced for non-small cell lung cancer and malignant pleural mesothelioma protocols.
Selective oestrogen receptor modulator in USP/EP/BP grade for tablet formulation manufacturing. Sourced for oestrogen receptor-positive breast cancer treatment and chemoprevention product lines.
Oral alkylating agent in pharmaceutical grade for capsule formulation manufacturing. Sourced for glioblastoma, anaplastic astrocytoma, and melanoma brain metastases treatment protocols.
Imidazole bisphosphonate in pharmaceutical grade (anhydrous and monohydrate forms available) for IV solution formulation manufacturing. Sourced for cancer bone metastases and hypercalcemia of malignancy treatment protocols.